麻豆原创 Analysis and Insights: Global Drug Discovery Assays 麻豆原创
The global Drug Discovery Assays market is projected to grow from US$ 7779.2 million in 2024 to US$ 12900 million by 2030, at a Compound Annual Growth Rate (CAGR) of 8.8% during the forecast period.
The Drug Discovery Assays market is a fundamental and dynamic sector within the pharmaceutical and biotechnology industry, offering a wide array of techniques and tools to identify and validate potential drug candidates. These assays encompass various approaches, such as high-throughput screening, cell-based assays, biochemical assays, and target-based assays, which are vital in the drug discovery process, from target identification to lead optimization. They are known for their ability to provide critical insights into the pharmacological and toxicological properties of compounds, facilitating the development of novel drugs and therapies. The market is characterized by ongoing technological advancements, automation, and the integration of artificial intelligence and machine learning to enhance the efficiency and accuracy of drug discovery processes. Leading providers in the life sciences and biotechnology sector, including PerkinElmer, Thermo Fisher Scientific, and Promega Corporation, focus on delivering innovative assay technologies and platforms that cater to the evolving needs of pharmaceutical companies and research institutions. As the pharmaceutical industry continues to advance toward personalized medicine, precision therapeutics, and the development of treatments for various diseases, the Drug Discovery Assays market is poised for sustained growth, offering indispensable tools for accelerating drug discovery, improving drug safety, and enhancing the efficiency of bringing new medications to market.
Report Covers:
This report presents an overview of global market for Drug Discovery Assays market size. Analyses of the global market trends, with historic market revenue data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.
This report researches the key producers of Drug Discovery Assays, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Drug Discovery Assays, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Drug Discovery Assays revenue, market share and industry ranking of main companies, data from 2019 to 2024. Identification of the major stakeholders in the global Drug Discovery Assays market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2019 to 2030. Evaluation and forecast the market size for Drug Discovery Assays revenue, projected growth trends, production technology, application and end-user industry.
麻豆原创 Segmentation
By Company
Thermo Fisher Scientific
Danaher
Becton Dickinson
GE Healthcare
Merck
Lonza
PerkinElmer, Inc.
Charles River Laboratories, Inc.
Cell Signaling Technologies
Cisbio
Cell Biolabs, Inc.
Promega
Pfizer
GSK
Agilent
Eli Lilly and Company
Roche
Bayer
Abbott
AstraZeneca
Shimadzu
Segment by Type
Consumables
Instruments
Services
Software
Segment by Application
Pharmaceutical and Biotechnology Companies
Academic and Government Institutions
Contract Research Organizations
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of Drug Discovery Assays in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Drug Discovery Assays companies鈥� competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America (US & Canada) by Type, by Application and by country, revenue for each segment.
Chapter 7: Europe by Type, by Application and by country, revenue for each segment.
Chapter 8: China by Type, and by Application, revenue for each segment.
Chapter 9: Asia (excluding China) by Type, by Application and by region, revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by Type, by Application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Drug Discovery Assays revenue, gross margin, and recent development, etc.
Chapter 12: Analyst's Viewpoints/Conclusions
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Drug Discovery Assays 麻豆原创 Size Growth Rate by Type, 2019 VS 2023 VS 2030
1.2.2 Consumables
1.2.3 Instruments
1.2.4 Services
1.2.5 Software
1.3 麻豆原创 by Application
1.3.1 Global Drug Discovery Assays 麻豆原创 Size Growth Rate by Application, 2019 VS 2023 VS 2030
1.3.2 Pharmaceutical and Biotechnology Companies
1.3.3 Academic and Government Institutions
1.3.4 Contract Research Organizations
1.3.5 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Drug Discovery Assays 麻豆原创 Perspective (2019-2030)
2.2 Global Drug Discovery Assays Growth Trends by Region
2.2.1 Drug Discovery Assays 麻豆原创 Size by Region: 2019 VS 2023 VS 2030
2.2.2 Drug Discovery Assays Historic 麻豆原创 Size by Region (2019-2024)
2.2.3 Drug Discovery Assays Forecasted 麻豆原创 Size by Region (2025-2030)
2.3 Drug Discovery Assays 麻豆原创 Dynamics
2.3.1 Drug Discovery Assays Industry Trends
2.3.2 Drug Discovery Assays 麻豆原创 Drivers
2.3.3 Drug Discovery Assays 麻豆原创 Challenges
2.3.4 Drug Discovery Assays 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Revenue Drug Discovery Assays by Players
3.1.1 Global Drug Discovery Assays Revenue by Players (2019-2024)
3.1.2 Global Drug Discovery Assays Revenue 麻豆原创 Share by Players (2019-2024)
3.2 Global Drug Discovery Assays 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players of Drug Discovery Assays, Ranking by Revenue, 2022 VS 2023 VS 2024
3.4 Global Drug Discovery Assays 麻豆原创 Concentration Ratio
3.4.1 Global Drug Discovery Assays 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Drug Discovery Assays Revenue in 2023
3.5 Global Key Players of Drug Discovery Assays Head office and Area Served
3.6 Global Key Players of Drug Discovery Assays, Product and Application
3.7 Global Key Players of Drug Discovery Assays, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Drug Discovery Assays Breakdown Data by Type
4.1 Global Drug Discovery Assays Historic 麻豆原创 Size by Type (2019-2024)
4.2 Global Drug Discovery Assays Forecasted 麻豆原创 Size by Type (2025-2030)
5 Drug Discovery Assays Breakdown Data by Application
5.1 Global Drug Discovery Assays Historic 麻豆原创 Size by Application (2019-2024)
5.2 Global Drug Discovery Assays Forecasted 麻豆原创 Size by Application (2025-2030)
6 North America
6.1 North America Drug Discovery Assays 麻豆原创 Size (2019-2030)
6.2 North America Drug Discovery Assays 麻豆原创 Size by Type
6.2.1 North America Drug Discovery Assays 麻豆原创 Size by Type (2019-2024)
6.2.2 North America Drug Discovery Assays 麻豆原创 Size by Type (2025-2030)
6.2.3 North America Drug Discovery Assays 麻豆原创 Share by Type (2019-2030)
6.3 North America Drug Discovery Assays 麻豆原创 Size by Application
6.3.1 North America Drug Discovery Assays 麻豆原创 Size by Application (2019-2024)
6.3.2 North America Drug Discovery Assays 麻豆原创 Size by Application (2025-2030)
6.3.3 North America Drug Discovery Assays 麻豆原创 Share by Application (2019-2030)
6.4 North America Drug Discovery Assays 麻豆原创 Size by Country
6.4.1 North America Drug Discovery Assays 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
6.4.2 North America Drug Discovery Assays 麻豆原创 Size by Country (2019-2024)
6.4.3 North America Drug Discovery Assays 麻豆原创 Size by Country (2025-2030)
6.4.4 U.S.
6.4.5 Canada
7 Europe
7.1 Europe Drug Discovery Assays 麻豆原创 Size (2019-2030)
7.2 Europe Drug Discovery Assays 麻豆原创 Size by Type
7.2.1 Europe Drug Discovery Assays 麻豆原创 Size by Type (2019-2024)
7.2.2 Europe Drug Discovery Assays 麻豆原创 Size by Type (2025-2030)
7.2.3 Europe Drug Discovery Assays 麻豆原创 Share by Type (2019-2030)
7.3 Europe Drug Discovery Assays 麻豆原创 Size by Application
7.3.1 Europe Drug Discovery Assays 麻豆原创 Size by Application (2019-2024)
7.3.2 Europe Drug Discovery Assays 麻豆原创 Size by Application (2025-2030)
7.3.3 Europe Drug Discovery Assays 麻豆原创 Share by Application (2019-2030)
7.4 Europe Drug Discovery Assays 麻豆原创 Size by Country
7.4.1 Europe Drug Discovery Assays 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
7.4.2 Europe Drug Discovery Assays 麻豆原创 Size by Country (2019-2024)
7.4.3 Europe Drug Discovery Assays 麻豆原创 Size by Country (2025-2030)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 China
8.1 China Drug Discovery Assays 麻豆原创 Size (2019-2030)
8.2 China Drug Discovery Assays 麻豆原创 Size by Type
8.2.1 China Drug Discovery Assays 麻豆原创 Size by Type (2019-2024)
8.2.2 China Drug Discovery Assays 麻豆原创 Size by Type (2025-2030)
8.2.3 China Drug Discovery Assays 麻豆原创 Share by Type (2019-2030)
8.3 China Drug Discovery Assays 麻豆原创 Size by Application
8.3.1 China Drug Discovery Assays 麻豆原创 Size by Application (2019-2024)
8.3.2 China Drug Discovery Assays 麻豆原创 Size by Application (2025-2030)
8.3.3 China Drug Discovery Assays 麻豆原创 Share by Application (2019-2030)
9 Asia (excluding China)
9.1 Asia Drug Discovery Assays 麻豆原创 Size (2019-2030)
9.2 Asia Drug Discovery Assays 麻豆原创 Size by Type
9.2.1 Asia Drug Discovery Assays 麻豆原创 Size by Type (2019-2024)
9.2.2 Asia Drug Discovery Assays 麻豆原创 Size by Type (2025-2030)
9.2.3 Asia Drug Discovery Assays 麻豆原创 Share by Type (2019-2030)
9.3 Asia Drug Discovery Assays 麻豆原创 Size by Application
9.3.1 Asia Drug Discovery Assays 麻豆原创 Size by Application (2019-2024)
9.3.2 Asia Drug Discovery Assays 麻豆原创 Size by Application (2025-2030)
9.3.3 Asia Drug Discovery Assays 麻豆原创 Share by Application (2019-2030)
9.4 Asia Drug Discovery Assays 麻豆原创 Size by Region
9.4.1 Asia Drug Discovery Assays 麻豆原创 Size by Region: 2019 VS 2023 VS 2030
9.4.2 Asia Drug Discovery Assays 麻豆原创 Size by Region (2019-2024)
9.4.3 Asia Drug Discovery Assays 麻豆原创 Size by Region (2025-2030)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
9.4.9 Australia
10 Middle East, Africa, and Latin America
10.1 Middle East, Africa, and Latin America Drug Discovery Assays 麻豆原创 Size (2019-2030)
10.2 Middle East, Africa, and Latin America Drug Discovery Assays 麻豆原创 Size by Type
10.2.1 Middle East, Africa, and Latin America Drug Discovery Assays 麻豆原创 Size by Type (2019-2024)
10.2.2 Middle East, Africa, and Latin America Drug Discovery Assays 麻豆原创 Size by Type (2025-2030)
10.2.3 Middle East, Africa, and Latin America Drug Discovery Assays 麻豆原创 Share by Type (2019-2030)
10.3 Middle East, Africa, and Latin America Drug Discovery Assays 麻豆原创 Size by Application
10.3.1 Middle East, Africa, and Latin America Drug Discovery Assays 麻豆原创 Size by Application (2019-2024)
10.3.2 Middle East, Africa, and Latin America Drug Discovery Assays 麻豆原创 Size by Application (2025-2030)
10.3.3 Middle East, Africa, and Latin America Drug Discovery Assays 麻豆原创 Share by Application (2019-2030)
10.4 Middle East, Africa, and Latin America Drug Discovery Assays 麻豆原创 Size by Country
10.4.1 Middle East, Africa, and Latin America Drug Discovery Assays 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
10.4.2 Middle East, Africa, and Latin America Drug Discovery Assays 麻豆原创 Size by Country (2019-2024)
10.4.3 Middle East, Africa, and Latin America Drug Discovery Assays 麻豆原创 Size by Country (2025-2030)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Saudi Arabia
10.4.8 Israel
10.4.9 GCC Countries
11 Key Players Profiles
11.1 Thermo Fisher Scientific
11.1.1 Thermo Fisher Scientific Company Details
11.1.2 Thermo Fisher Scientific Business Overview
11.1.3 Thermo Fisher Scientific Drug Discovery Assays Introduction
11.1.4 Thermo Fisher Scientific Revenue in Drug Discovery Assays Business (2019-2024)
11.1.5 Thermo Fisher Scientific Recent Developments
11.2 Danaher
11.2.1 Danaher Company Details
11.2.2 Danaher Business Overview
11.2.3 Danaher Drug Discovery Assays Introduction
11.2.4 Danaher Revenue in Drug Discovery Assays Business (2019-2024)
11.2.5 Danaher Recent Developments
11.3 Becton Dickinson
11.3.1 Becton Dickinson Company Details
11.3.2 Becton Dickinson Business Overview
11.3.3 Becton Dickinson Drug Discovery Assays Introduction
11.3.4 Becton Dickinson Revenue in Drug Discovery Assays Business (2019-2024)
11.3.5 Becton Dickinson Recent Developments
11.4 GE Healthcare
11.4.1 GE Healthcare Company Details
11.4.2 GE Healthcare Business Overview
11.4.3 GE Healthcare Drug Discovery Assays Introduction
11.4.4 GE Healthcare Revenue in Drug Discovery Assays Business (2019-2024)
11.4.5 GE Healthcare Recent Developments
11.5 Merck
11.5.1 Merck Company Details
11.5.2 Merck Business Overview
11.5.3 Merck Drug Discovery Assays Introduction
11.5.4 Merck Revenue in Drug Discovery Assays Business (2019-2024)
11.5.5 Merck Recent Developments
11.6 Lonza
11.6.1 Lonza Company Details
11.6.2 Lonza Business Overview
11.6.3 Lonza Drug Discovery Assays Introduction
11.6.4 Lonza Revenue in Drug Discovery Assays Business (2019-2024)
11.6.5 Lonza Recent Developments
11.7 PerkinElmer, Inc.
11.7.1 PerkinElmer, Inc. Company Details
11.7.2 PerkinElmer, Inc. Business Overview
11.7.3 PerkinElmer, Inc. Drug Discovery Assays Introduction
11.7.4 PerkinElmer, Inc. Revenue in Drug Discovery Assays Business (2019-2024)
11.7.5 PerkinElmer, Inc. Recent Developments
11.8 Charles River Laboratories, Inc.
11.8.1 Charles River Laboratories, Inc. Company Details
11.8.2 Charles River Laboratories, Inc. Business Overview
11.8.3 Charles River Laboratories, Inc. Drug Discovery Assays Introduction
11.8.4 Charles River Laboratories, Inc. Revenue in Drug Discovery Assays Business (2019-2024)
11.8.5 Charles River Laboratories, Inc. Recent Developments
11.9 Cell Signaling Technologies
11.9.1 Cell Signaling Technologies Company Details
11.9.2 Cell Signaling Technologies Business Overview
11.9.3 Cell Signaling Technologies Drug Discovery Assays Introduction
11.9.4 Cell Signaling Technologies Revenue in Drug Discovery Assays Business (2019-2024)
11.9.5 Cell Signaling Technologies Recent Developments
11.10 Cisbio
11.10.1 Cisbio Company Details
11.10.2 Cisbio Business Overview
11.10.3 Cisbio Drug Discovery Assays Introduction
11.10.4 Cisbio Revenue in Drug Discovery Assays Business (2019-2024)
11.10.5 Cisbio Recent Developments
11.11 Cell Biolabs, Inc.
11.11.1 Cell Biolabs, Inc. Company Details
11.11.2 Cell Biolabs, Inc. Business Overview
11.11.3 Cell Biolabs, Inc. Drug Discovery Assays Introduction
11.11.4 Cell Biolabs, Inc. Revenue in Drug Discovery Assays Business (2019-2024)
11.11.5 Cell Biolabs, Inc. Recent Developments
11.12 Promega
11.12.1 Promega Company Details
11.12.2 Promega Business Overview
11.12.3 Promega Drug Discovery Assays Introduction
11.12.4 Promega Revenue in Drug Discovery Assays Business (2019-2024)
11.12.5 Promega Recent Developments
11.13 Pfizer
11.13.1 Pfizer Company Details
11.13.2 Pfizer Business Overview
11.13.3 Pfizer Drug Discovery Assays Introduction
11.13.4 Pfizer Revenue in Drug Discovery Assays Business (2019-2024)
11.13.5 Pfizer Recent Developments
11.14 GSK
11.14.1 GSK Company Details
11.14.2 GSK Business Overview
11.14.3 GSK Drug Discovery Assays Introduction
11.14.4 GSK Revenue in Drug Discovery Assays Business (2019-2024)
11.14.5 GSK Recent Developments
11.15 Agilent
11.15.1 Agilent Company Details
11.15.2 Agilent Business Overview
11.15.3 Agilent Drug Discovery Assays Introduction
11.15.4 Agilent Revenue in Drug Discovery Assays Business (2019-2024)
11.15.5 Agilent Recent Developments
11.16 Eli Lilly and Company
11.16.1 Eli Lilly and Company Company Details
11.16.2 Eli Lilly and Company Business Overview
11.16.3 Eli Lilly and Company Drug Discovery Assays Introduction
11.16.4 Eli Lilly and Company Revenue in Drug Discovery Assays Business (2019-2024)
11.16.5 Eli Lilly and Company Recent Developments
11.17 Roche
11.17.1 Roche Company Details
11.17.2 Roche Business Overview
11.17.3 Roche Drug Discovery Assays Introduction
11.17.4 Roche Revenue in Drug Discovery Assays Business (2019-2024)
11.17.5 Roche Recent Developments
11.18 Bayer
11.18.1 Bayer Company Details
11.18.2 Bayer Business Overview
11.18.3 Bayer Drug Discovery Assays Introduction
11.18.4 Bayer Revenue in Drug Discovery Assays Business (2019-2024)
11.18.5 Bayer Recent Developments
11.19 Abbott
11.19.1 Abbott Company Details
11.19.2 Abbott Business Overview
11.19.3 Abbott Drug Discovery Assays Introduction
11.19.4 Abbott Revenue in Drug Discovery Assays Business (2019-2024)
11.19.5 Abbott Recent Developments
11.20 AstraZeneca
11.20.1 AstraZeneca Company Details
11.20.2 AstraZeneca Business Overview
11.20.3 AstraZeneca Drug Discovery Assays Introduction
11.20.4 AstraZeneca Revenue in Drug Discovery Assays Business (2019-2024)
11.20.5 AstraZeneca Recent Developments
11.21 Shimadzu
11.21.1 Shimadzu Company Details
11.21.2 Shimadzu Business Overview
11.21.3 Shimadzu Drug Discovery Assays Introduction
11.21.4 Shimadzu Revenue in Drug Discovery Assays Business (2019-2024)
11.21.5 Shimadzu Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Thermo Fisher Scientific
Danaher
Becton Dickinson
GE Healthcare
Merck
Lonza
PerkinElmer, Inc.
Charles River Laboratories, Inc.
Cell Signaling Technologies
Cisbio
Cell Biolabs, Inc.
Promega
Pfizer
GSK
Agilent
Eli Lilly and Company
Roche
Bayer
Abbott
AstraZeneca
Shimadzu
听
听
*If Applicable.
